Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiangning Huang

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Journal of Applied Microbiology|August 3, 2024
Modification of carbapenemase inhibition test and comparison of its performance with NG-Test CARBA 5 for detection of carbapenemase-producing EnterobacteralesYue Wang, Xiangning Huang, Dandan Yin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2016
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial ProgramFlorian M Wagenlehner, Jack D Sobel, Paul Newell, et al.
Gastroenterology Report|February 16, 2026
Secondary follicle-like TLS as a protective factor in pMMR rectal cancer: insights into its regional distribution and prognostic valueJingwen Qi, Han Zhang, Guannan Wang, et al.
Pharmacology Research & Perspectives|April 28, 2025
Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung CancerMartin Johnson, Yu-Wei Lin, Henning Schmidt, et al.
British Journal of Clinical Pharmacology|August 19, 2024
Exposure-response modelling of osimertinib in patients with non-small cell lung cancerMartin Johnson, Yu-Wei Lin, Henning Schmidt, et al.
Critical Care (London, England)|February 21, 2012
A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shockPeter E Morris, Brian Zeno, Andrew C Bernard, et al.
Clinical Lung Cancer|March 5, 2023
Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2Yasuhiro Tsutani, Jonathan W Goldman, Sanja Dacic, et al.
Frontiers in Cellular and Infection Microbiology|January 20, 2022
Occurrence of NDM-1, VIM-1, and OXA-10 Co-Producing <i>Providencia rettgeri</i> Clinical Isolate in ChinaSiquan Shen, Xiangning Huang, Qingyu Shi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancerThomas John, Hiroaki Akamatsu, Angelo Delmonte, et al.
Journal of Ethnopharmacology|December 9, 2017
Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed ratJiajia Wang, Xiaofang Li, Shugui He, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Journal of Applied Microbiology|August 3, 2024
Modification of carbapenemase inhibition test and comparison of its performance with NG-Test CARBA 5 for detection of carbapenemase-producing EnterobacteralesYue Wang, Xiangning Huang, Dandan Yin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2016
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial ProgramFlorian M Wagenlehner, Jack D Sobel, Paul Newell, et al.
Gastroenterology Report|February 16, 2026
Secondary follicle-like TLS as a protective factor in pMMR rectal cancer: insights into its regional distribution and prognostic valueJingwen Qi, Han Zhang, Guannan Wang, et al.
Pharmacology Research & Perspectives|April 28, 2025
Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung CancerMartin Johnson, Yu-Wei Lin, Henning Schmidt, et al.
British Journal of Clinical Pharmacology|August 19, 2024
Exposure-response modelling of osimertinib in patients with non-small cell lung cancerMartin Johnson, Yu-Wei Lin, Henning Schmidt, et al.
Critical Care (London, England)|February 21, 2012
A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shockPeter E Morris, Brian Zeno, Andrew C Bernard, et al.
Clinical Lung Cancer|March 5, 2023
Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2Yasuhiro Tsutani, Jonathan W Goldman, Sanja Dacic, et al.
Frontiers in Cellular and Infection Microbiology|January 20, 2022
Occurrence of NDM-1, VIM-1, and OXA-10 Co-Producing <i>Providencia rettgeri</i> Clinical Isolate in ChinaSiquan Shen, Xiangning Huang, Qingyu Shi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancerThomas John, Hiroaki Akamatsu, Angelo Delmonte, et al.
Journal of Ethnopharmacology|December 9, 2017
Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed ratJiajia Wang, Xiaofang Li, Shugui He, et al.
Pageof 6